The analysis for Arcus Biosciences Inc. (RCUS) stock designates it as a Strong Sell Candidate with an overall system score of -5.056. The current price is $21.53, reflecting a 14.45% decline on the last trading day. News indicates a significant plunge due to the halting of a Phase 3 cancer study, serving as an immediate negative catalyst, despite a prior 300% run-up. Management plans to reallocate resources to other programs, and increased volatility and potential additional selling are anticipated. The company recently completed a $250 million equity raise with new inducement grants. Executive stock sales and a recent quarterly loss contribute to a cautious sentiment. Technical signals present a mixed picture: short-term indicators include a buy signal from MACD and Bollinger Bands, while Pivots and Long Moving Average indicate sell signals. Long-term Moving Averages show a sell signal from the Short MA (2 days ago), and buy signals from the Long MA (112 days ago) and Cross MA35/MA100 (104 days ago). The stock exhibits high weekly volatility at 7.11%. Immediate resistance levels are identified at $24.28 and $25.43, with support levels at $20.35 and $20.29. The Price-to-Earnings (P/E) ratio is negative at -6.57. Insider trading indicates a positive insider power of 78.395, with more shares purchased (7.498 million) than sold (558,540) in the last 100 transactions. The conclusion forecasts weak performance for RCUS in the next few days or weeks, reiterating a negative evaluation and a downgrade from Buy to Strong Sell. Although the stock is considered undervalued and is predicted to open higher on the next trading day by $0.427, trading at $21.95, the overarching sentiment points to further decline. An inferred short-term target price is $20.29, with a failure bound at $24.28, reflecting a bearish predicted trend for the upcoming week.